OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced this morning it plans for a US launch of LP(LDL)
Stephen O’Hara, Chief Executive Officr at OptiBiotix Health PLC (LON:OPTI) talks to Proactive Investors about extending a key manufacturing and supply agreement.
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care announces that, further to the European manufacturing and supply agreement with
OptiBiotix Health’s Stephen O’Hara discusses the recent share price movement, their deal pipeline, the 39 potential RNS’s that could be announced in the following months & what this all means for investors in this exclusive interview with DirectorsTalk
Optibiotix Health Plc (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about the recent share price movement. Stephen also talks about the potential for 39 RNS’s that could be announced over
Stephen O’Hara, Chief Executive Officer at OptiBiotix Health PLC (LON:OPTI) talks to Proactive Investors about the significant milestone with first sales in Germany of a new range of cholesterol-lowering capsules
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced this morning that HLH BioPharma Vertriebs GmbH have achieved product
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced this morning that it has agreed to develop and supply
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announced this morning successful human taste studies in its SweetBiotix(R) product development programme.
OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, has this morning told DirectorsTalk it has entered into a three
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
